Researchers unveiled a ferroptosis‑inducing nanotherapy that targets cancer‑associated fibroblasts (CAFs) within colorectal tumors, reversing CAF‑driven fibrosis and restoring a microenvironment permissive to therapy. The nanoparticle platform selectively triggered lipid peroxidation in CAFs, collapsing their pro‑tumor signaling and reducing stromal barriers to drug penetration. Preclinical models reported tumor‑stroma remodeling, improved delivery of co‑administered agents, and slowed tumor progression, suggesting a stroma‑first strategy to sensitize resistant colorectal cancers. The approach emphasizes ferroptosis—an iron‑dependent cell death—as a means to dismantle protective niches in solid tumors. Translational teams should evaluate combination regimens, dosing windows to spare normal stroma, and biomarkers for ferroptosis susceptibility to design first‑in‑human studies. Source: Wang et al., experimental oncology report.